Reuters Features Medical Marijuana, Inc.’s Major Investment Company AXIM Biotech In Article Citing Company’s Development Of Marijuana-Based Painkiller To Combat Opioid Crisis

NEW YORK, June 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, was featured in a Reuters article focused on companies that are developing marijuana-based painkillers to help combat America’s opioid crisis.

The June 23, 2017 article “High hopes ride on marijuana painkillers amid opioid crisis,” which also ran in Fortune, Scientific American, CNBC, Business Insider, and the Daily Mail, features AXIM Biotech for the preclinical studies it is conducting on a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment, for which it expects to submit an FDA application to start a trial on opioid-dependent patients this year.

The article states: “The companies are targeting more than 100 million Americans who suffer from chronic pain, and are dependent on opioid painkillers such as Vicodin, or addicted to street opiates including heroin.”

“We are grateful that Reuters is covering companies like AXIM that are developing alternatives for the roughly 2.5 million Americans addicted to opioids,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “The future of pain management, a $100 billion market, may be a high dose of cannabis and a low dose of opioids. Already, we are seeing the incidence of prescription drug overdose death 25% lower in states where medical cannabis is legal, presumably because patients are able to combine natural botanical cannabis and use lower dose opioids to control pain.”

On June 23, 2017, AXIM Biotech announced that it filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. The chewing gum may also be used for treatment of chronic pain.

About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About AXIM®
AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
[email protected]

Investor Relations Contact:
Shiwei Yin, Grayling
[email protected]
P. +1 646 284-9474
Lucia Domville, Grayling
[email protected]
P. +1 646 284-9416

Corporate Contact Info:
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227